Co je nového v léčbě dyslipidemií
| Title in English | What's new in the treatment of dyslipidemia |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Acta medicinae |
| MU Faculty or unit | |
| Citation | |
| Field | Other specializations of internal medicine |
| Keywords | LDL-cholesterol; statins; ezetimibe; PCSK9 inhibitors |
| Description | This year were published new European recommendations for cardiovascular disease prevention in clinical practice, which reflect also some new information regarding the treatment of patients with dyslipidaemia: specify some the target values of blood lipids and also an indication of some lipid lowering drugs. Primary hypolipidemic drugs remain statins. To further reduce LDL cholesterol level, ezetimibe can be added to combination with statins. There are already evidence that ezetimibe reduces not only LDL-cholesterol, but also the risk of coronary events. Combination of a statin with fenofibrate may be considered in patients with combined dyslipidemia (elevated triglycerides, low HDL-cholesterol). Next year the new hypolipidemic drug - PCSK9 inhibitors - should be available. For patients with homozygous familial hypercholesterolemia treatment with lomitapid is approved. |